{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:48:19Z","timestamp":1782197299046,"version":"3.54.5"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>SARS-CoV-2 laboratory testing data were collected by the U.S. Centers for Disease Control and Prevention for surveillance during the COVID-19 pandemic response. Understanding how these existing data correlate and diverge can help guide their use and interpretation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We evaluated COVID-19 Electronic Laboratory Reporting (CELR), the National Respiratory and Enteric Virus Surveillance System (NREVSS), Increasing Community Access to Testing, Treatment and Response (ICATT) program, and commercial laboratory data from 2020 to 2024. SARS-CoV-2 testing volume, viral activity, and viral activity trends were calculated for each source during periods marked by key events. Key events included Delta and Omicron variant emergence, at-home testing availability, and public health emergency conclusion. Viral activity was characterized by percent positivity, the median percent of tests positive for SARS-CoV-2. Viral activity trends were measured using Spearman\u2019s correlation coefficients of normalized percent positivity between NREVSS and each of the data sources, along with match rates between the two sources from weekly trajectory categorization (increasing, stable, decreasing) comparisons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SARS-CoV-2 testing volume decreased across time, most notably since January 2022. Viral activity measures showed that CELR (8.4%) and NREVSS (7.7%) had lower median weekly percent positivity compared to ICATT (18.5%) and commercial laboratories (11.0%). Viral activity trends between NREVSS and CELR (\n                      <jats:italic>\u03c1<\/jats:italic>\n                      \u202f=\u202f0.93) and NREVSS and commercial laboratory (\n                      <jats:italic>\u03c1<\/jats:italic>\n                      \u202f=\u202f0.85) were highly correlated, and less correlated between NREVSS and ICATT (\n                      <jats:italic>\u03c1<\/jats:italic>\n                      \u202f=\u202f0.58). Week-to-week trajectory match rates indicated concordant viral trends across data sources with 89% for CELR, 79% for commercial laboratories, and 67% for ICATT when compared to NREVSS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>ICATT and commercial laboratory data sources consistently reported higher activity levels than CELR and NREVSS, suggesting differences in testing and care-seeking among the underlying populations represented, and the effects of varying reporting practices over time. However, trend correlations with NREVSS were high and few differences were observed in week-to-week trajectories. While these findings may be in part due to overlap in data sources, they also suggest that viral activity trends were relatively consistent across sources. A broad set of laboratory-based surveillance data sources effectively captured trends in SARS-CoV-2 circulation despite the evolving nature of testing and reporting during and after the COVID-19 pandemic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1827546","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:18:34Z","timestamp":1782195514000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative evaluation of SARS-CoV-2 laboratory testing data sources for U.S. COVID-19 public health surveillance, 2020\u20132024"],"prefix":"10.3389","volume":"14","author":[{"given":"Alisha","family":"Kalangara","sequence":"first","affiliation":[{"name":"Goldbelt Professional Services","place":["Chesapeake, VA, United States"]},{"name":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Millard","sequence":"additional","affiliation":[{"name":"Goldbelt Professional Services","place":["Chesapeake, VA, United States"]},{"name":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber K.","family":"Winn","sequence":"additional","affiliation":[{"name":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia A.","family":"Aden","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Del Guercio","sequence":"additional","affiliation":[{"name":"Deloitte Consulting LLP","place":["Atlanta, GA, United States"]},{"name":"Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jourdan","family":"DeVies","sequence":"additional","affiliation":[{"name":"Office of Public Health Data, Surveillance, and Technology, Office of the Director, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Dietz","sequence":"additional","affiliation":[{"name":"Office of Public Health Data, Surveillance, and Technology, Office of the Director, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Godoshian","sequence":"additional","affiliation":[{"name":"Office of Readiness and Response, Office of the Director, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Hall","sequence":"additional","affiliation":[{"name":"Deloitte Consulting LLP","place":["Atlanta, GA, United States"]},{"name":"Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Jue","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Miller","sequence":"additional","affiliation":[{"name":"Office of Laboratory Systems and Response, Office of the Director, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Billig Rose","sequence":"additional","affiliation":[{"name":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Office of Readiness and Response, Office of the Director, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Silk","sequence":"additional","affiliation":[{"name":"Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"ref1","first-page":"1","article-title":"Framework for evaluating public health surveillance systems for early detection of outbreaks: recommendations from the CDC working group","volume":"53","author":"Buehler","year":"2004","journal-title":"MMWR Recomm Rep"},{"key":"ref2","volume-title":"Public Health Surveillance for COVID-19: Interim Guidance","year":"2022"},{"key":"ref3","year":"2024"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.hlpt.2020.08.007","article-title":"COVID-19 pandemic in the United States","volume":"9","author":"Bergquist","year":"2020","journal-title":"Health Policy Technol"},{"key":"ref5","volume-title":"Fact Sheet: End of the COVID-19 Public Health Emergency","year":"2023"},{"key":"ref6","year":"2024"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.15585\/mmwr.mm7219e1","article-title":"COVID-19 surveillance after expiration of the public health emergency declaration - United States, May 11, 2023","volume":"72","author":"Silk","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.15585\/mmwr.mm7219e2","article-title":"Correlations and timeliness of COVID-19 surveillance data sources and indicators - United States, October 1, 2020-March 22, 2023","volume":"72","author":"Scobie","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref9","year":"2024"},{"key":"ref10","volume-title":"Centers for Disease Control and Prevention. Percent Positivity of COVID-19 Nucleic Acid Amplification Tests in the Past Week by HHS Region, National Respiratory and Enteric Virus Surveillance System (NREVSS)","year":""},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.15585\/mmwr.mm7049a3","article-title":"Community-based testing sites for SARS-CoV-2\u2014United States, march 2020\u2013November 2021","volume":"70","author":"Miller","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref12","first-page":"CAT.25.0149","article-title":"The Increasing Community Access to Testing, Treatment, and Response Program \u2014 A Model for Future Public Health Emergency Response","volume-title":"NEJM Catalyst","author":"Tsai","year":"2026"},{"key":"ref13","year":"2024"},{"key":"ref14","year":"2024"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.15585\/mmwr.mm7106a4","article-title":"Genomic surveillance for SARS-CoV-2 variants: predominance of the Delta (B.1.617.2) and omicron (B.1.1.529) variants - United States, June 2021-January 2022","volume":"71","author":"Lambrou","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.15585\/mmwr.mm7103a5","article-title":"Notes from the field: early evidence of the SARS-CoV-2 B.1.1.529 (omicron) variant in community wastewater - United States, November-December 2021","volume":"71","author":"Kirby","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.15585\/mmwr.mm7050e1","article-title":"SARS-CoV-2 B.1.1.529 (omicron) variant - United States, December 1-8, 2021","volume":"70","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref18","year":"2023"},{"key":"ref19","volume-title":"Weeks - NNDSS case definitions","year":""},{"key":"ref20","volume-title":"National Center for Health Statistics Data Presentation Standards for Rates and Counts. Other NCHS Survey or Data System.2(200)","author":"Parker","year":""},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.15585\/mmwr.mm7132a2","article-title":"Notes from the field: school-based and laboratory-based reporting of positive COVID-19 test results among school-aged children - New York, September 11, 2021-April 29, 2022","volume":"71","author":"Shircliff","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.annepidem.2023.11.009","article-title":"Home testing for SARS-CoV-2 and impact on surveillance in New York state","volume":"91","author":"Mitchell","year":"2024","journal-title":"Ann Epidemiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"7314","DOI":"10.1007\/s12144-021-02397-w","article-title":"Do we experience pandemic fatigue? Current state, predictors, and prevention","volume":"41","author":"Haktanir","year":"2022","journal-title":"Curr Psychol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.15585\/mmwr.mm7113e1","article-title":"Use of at-home COVID-19 tests - United States, august 23, 2021-march 12, 2022","volume":"71","author":"Rader","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S2468-2667(24)00279-2","article-title":"The SARS-CoV-2 test scale-up in the USA: an analysis of the number of tests produced and used over time and their modelled impact on the COVID-19 pandemic","volume":"10","author":"Santos","year":"2025","journal-title":"Lancet Public Health"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1126\/science.abm4915","article-title":"The changing epidemiology of SARS-CoV-2","volume":"375","author":"Koelle","year":"2022","journal-title":"Science"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"S139","DOI":"10.1093\/cid\/cit578","article-title":"Better tests, better care: improved diagnostics for infectious diseases","volume":"57","author":"Caliendo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3201\/eid3108.250451","article-title":"Estimated COVID-19 periodicity and correlation with SARS-CoV-2 spike protein S1 antigenic diversity","volume":"31","author":"Rose","year":"2025","journal-title":"United States Emerg Infect Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e0014424","DOI":"10.1128\/jcm.00144-24","article-title":"Proceedings of the clinical microbiology open 2023: discussions about pandemic preparedness","volume":"62","author":"Powell","year":"2024","journal-title":"J Clin Microbiol"},{"key":"ref30","year":"2021"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/jrh.12450","article-title":"A commentary on rural-urban disparities in COVID-19 testing rates per 100,000 and risk factors","volume":"37","author":"Souch","year":"2021","journal-title":"J Rural Health"},{"key":"ref32","year":"2019"},{"key":"ref33","year":"2023"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(21)02346-1","article-title":"Diagnostics for COVID-19: moving from pandemic response to control","volume":"399","author":"Peeling","year":"2022","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013705.pub3","article-title":"Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection","volume":"2022","author":"Dinnes","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.bbrc.2020.10.069","article-title":"Laboratory testing for the diagnosis of COVID-19","volume":"538","author":"Lai","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.15585\/mmwr.mm7132a1","article-title":"COVID-19 self-test data: challenges and opportunities - United States, October 31, 2021-June 11, 2022","volume":"71","author":"Ritchey","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.15585\/mmwr.mm7506a2","article-title":"Respiratory virus activity - United States, July 1, 2024-June 30, 2025","volume":"75","author":"Silk","year":"2026","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"938","DOI":"10.15585\/mmwr.mm7342a1","article-title":"Genomic surveillance for SARS-CoV-2 variants: circulation of omicron XBB and JN.1 lineages - United States, May 2023-September 2024","volume":"73","author":"Ma","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"29109","DOI":"10.1038\/s41598-025-10132-9","article-title":"A comparative analysis of the role of containment policies, vaccination strategies and virus variants in the COVID-19 pandemic across nine European countries","volume":"15","author":"Rancati","year":"2025","journal-title":"Sci Rep"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"e2022GH000771","DOI":"10.1029\/2022GH000771","article-title":"Assessing the effect of the U.S. vaccination program on the coronavirus positivity rate with a multivariate framework","volume":"7","author":"Sanchez-Vargas","year":"2023","journal-title":"GeoHealth"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1827546\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:18:36Z","timestamp":1782195516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1827546\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":41,"alternative-id":["10.3389\/fpubh.2026.1827546"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1827546","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1827546"}}